Entrada Therapeutics (TRDA) CFO sells 16,477 shares under 10b5-1 plan

Rhea-AI Filing Summary

Entrada Therapeutics, Inc. Chief Financial Officer Kory James Wentworth reported open-market sales of company common stock. He sold 5,089 shares on March 9, 2026 at a weighted average price of $13.0011 per share and 11,388 shares on March 10, 2026 at a weighted average price of $13.0151 per share. These transactions, totaling 16,477 shares, were executed pursuant to a Rule 10b5-1 trading plan adopted on March 6, 2025. After the most recent sale, he directly holds 121,510 shares of Entrada common stock.

Insider Trade Summary 10b5-1

Net Seller: 16,477 shares ($214,379)

Net Sell 2 txns

Insider WENTWORTH KORY JAMES

Role Chief Financial Officer

Sold 16,477 shs ($214K)

Type	Security	Shares	Price	Value
Sale	Common Stock	11,388	$13.0151	$148K
Sale	Common Stock	5,089	$13.0011	$66K

Holdings After Transaction: Common Stock — 121,510 shares (Direct)

Footnotes (1)

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.95 to $13.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.95 to $13.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WENTWORTH KORY JAMES

(Last) (First) (Middle)

C/O ENTRADA THERAPEUTICS, INC.

ONE DESIGN CENTER PLACE, SUITE 17-500

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Entrada Therapeutics, Inc. [ TRDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/09/2026		S(1)		5,089	D	$13.0011(2)	132,898	D
Common Stock	03/10/2026		S(1)		11,388	D	$13.0151(3)	121,510	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.95 to $13.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.95 to $13.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Jared Cohen, as Attorney-in-Fact	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Entrada Therapeutics (TRDA) report for its CFO?

Entrada’s CFO, Kory James Wentworth, reported selling 16,477 shares of common stock in two open-market transactions. The trades occurred on March 9 and 10, 2026, and were executed under a pre-established Rule 10b5-1 trading plan adopted in March 2025.

How many Entrada Therapeutics (TRDA) shares does the CFO hold after these sales?

After the latest reported sale, the CFO directly holds 121,510 shares of Entrada Therapeutics common stock. This figure reflects his remaining position following the March 10, 2026 transaction and provides context for the scale of the 16,477 shares sold across both days.

Were the Entrada Therapeutics (TRDA) CFO stock sales pre-planned under a Rule 10b5-1 plan?

Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan adopted on March 6, 2025. Such plans allow insiders to schedule trades in advance, which can reduce the significance of transaction timing as an indicator of their current views.

At what prices did the Entrada Therapeutics (TRDA) CFO sell his shares?

The CFO reported weighted average sale prices of $13.0011 per share for 5,089 shares on March 9, 2026 and $13.0151 per share for 11,388 shares on March 10, 2026. Actual trades occurred in ranges around these averages, as detailed in the footnotes.

Did the Entrada Therapeutics (TRDA) Form 4 include any option exercises or derivative transactions?

No derivative or option exercises are reported in this Form 4. Both transactions involve non-derivative common stock sales, and the derivative position summary is empty, indicating no option exercises or other derivative trades disclosed in this particular filing.